S
Simone Inkrot
Researcher at Charité
Publications - 20
Citations - 666
Simone Inkrot is an academic researcher from Charité. The author has contributed to research in topics: Heart failure & Bisoprolol. The author has an hindex of 11, co-authored 20 publications receiving 573 citations. Previous affiliations of Simone Inkrot include Waikato Hospital.
Papers
More filters
Journal ArticleDOI
Comparison of self-care behaviors of heart failure patients in 15 countries worldwide
Tiny Jaarsma,Anna Strömberg,Tuvia Ben Gal,Jan Cameron,Andrea Driscoll,Hans Dirk Duengen,Simone Inkrot,Tsuey Yuan Huang,Nguyen Ngoc Huyen,Naoko Kato,Stefan Köberich,Stefan Köberich,Josep Lupón,Debra K. Moser,Giovanni Pulignano,Eneida Rejane Rabelo,Jom Suwanno,David R. Thompson,Ercole Vellone,Rosaria Alvaro,Doris S.F. Yu,Barbara Riegel +21 more
TL;DR: Interventions that focus on specific self-care behaviors may be more effective than general educational programs and changes in some health care systems and national policies are needed to support patients with heart failure to increase theirSelf-care behavior.
Journal ArticleDOI
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial
Hans-Dirk Düngen,Svetlana Apostolović,Simone Inkrot,Elvis Tahirovic,Agnieszka Töpper,Felix Mehrhof,Christiane Prettin,Biljana Putnikovic,Aleksandar N. Neskovic,Mirjana Krotin,Dejan Sakač,Mitja Lainscak,Frank T. Edelmann,Rolf Wachter,Thomas Rau,Thomas Eschenhagen,Wolfram Doehner,Stefan D. Anker,Finn Waagstein,Christoph Herrmann-Lingen,G. Gelbrich,Rainer Dietz +21 more
TL;DR: The tolerability and clinical effects of two proven beta‐blockers in elderly patients with heart failure are compared to determine whether one agent is superior in terms of tolerability or optimal dosing.
Journal ArticleDOI
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial
Hans-Dirk Düngen,Svetlana Apostolović,Simone Inkrot,Elvis Tahirovic,Florian Krackhardt,Milan Pavlović,Biljana Putnikovic,Mitja Lainscak,Götz Gelbrich,Frank T. Edelmann,Rolf Wachter,Thomas Eschenhagen,Finn Waagstein,Ferenc Follath,Mathias Rauchhaus,Wilhelm Haverkamp,Karl-Josef Osterziel,Rainer Dietz +17 more
TL;DR: CIBIS-ELD is an investigator-initiated, multi-centre, 1:1 randomised, double-blind, phase III trial comparing bisoprolol and carvedilol in patients ≥65 years with systolic or diastolic CHF, and is the first large scale head to head beta-blockers trial in an elderly population with CHF.
Journal ArticleDOI
Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
Frank Edelmann,Lindy Musial-Bright,G. Gelbrich,Tobias Daniel Trippel,Sara Radenovic,Rolf Wachter,Simone Inkrot,Goran Loncar,Elvis Tahirovic,Vera Celic,Jovan Veskovic,Marija Zdravkovic,Mitja Lainscak,Svetlana Apostolović,Aleksandar N. Neskovic,Burkert Pieske,Hans-Dirk Düngen +16 more
TL;DR: Interestingly, beta-blockade had no effect on established and prognostic markers of diastolic function in either group, however, only HFrEF patients experienced considerable improvements in clinical parameters and left ventricular function.
Journal ArticleDOI
Heart rate following short‐term beta‐blocker titration predicts all‐cause mortality in elderly chronic heart failure patients: insights from the CIBIS‐ELD trial
Hans-Dirk Düngen,Lindy Musial-Bright,Simone Inkrot,Svetlana Apostolović,Frank T. Edelmann,Mitja Lainscak,Nikola Sekularac,Stefan Störk,Elvis Tahirovic,Verena Tscholl,Florian Krackhardt,Goran Loncar,Tobias Daniel Trippel,Götz Gelbrich +13 more
TL;DR: This pre‐specified analysis investigated the prognostic value of achieved heart rate after BB optimization on long‐term mortality and found it to be positive.